U.S. markets closed

Corcept Therapeutics Incorporated (CORT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
22.43-0.25 (-1.10%)
At close: 4:00PM EDT

22.43 0.00 (0.00%)
After hours: 5:11PM EDT

Corcept Therapeutics Incorporated

149 Commonwealth Drive
Menlo Park, CA 94025
United States
650 327 3270
http://www.corcept.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees236

Key Executives

NameTitlePayExercisedYear Born
Dr. Joseph K. BelanoffCo-Founder, Pres, CEO & Director1.45M8.41M1957
Mr. Sean MaduckChief Commercial Officer765.01kN/A1978
Dr. Andreas Grauer M.D.Chief Medical Officer784.58kN/A1961
Mr. Gary Charles RobbChief Bus. Officer & Sec.765.01k354.43k1963
Mr. Atabak MokariChief Financial OfficerN/AN/A1977
Mr. J. D. LyonChief Accounting OfficerN/AN/A1978
Dr. Hazel HuntChief Scientific OfficerN/AN/AN/A
Dr. Christopher Shayne James M.D.Director of Investor RelationsN/AN/AN/A
Donald E. LaferleSr. VPN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with serous ovarian tumors, as well as in Phase III clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator combined with Xtandi that is in open label dose finding trial to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.

Corporate Governance

Corcept Therapeutics Incorporated’s ISS Governance QualityScore as of April 1, 2021 is 7. The pillar scores are Audit: 8; Board: 5; Shareholder Rights: 7; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.